Sexually transmitted diseases (STDs) are infections that are transmitted from one person to another through sexual contact. STDs affect individuals of all ages, however, according to CDC, age group of 15‐24 accounts for half of all new STDs infections. Currently, STDs are the most common diseases in U.S., and as per CDC, about 19 million men and women are diagnosed with STDs each year. The disease is caused due to transmission of microbes (bacteria, virus, yeast, and parasites) during sexual intercourse. The disease is diagnosed using laboratory and point-of-care tests such as differential light scattering, ELISA, micro fluidics, and immunochromatographic test (ICTs).
Favorable reimbursement scenario for STD tests in the U.S. market is set to further drive the market growth. This report provides deep understanding of the laboratory claims for STD tests in the U.S. Claims for laboratory services must include an ICD-10-CM codes, which are found in the “ICD-10-CM Diagnosis Code” column of the laboratory services grid. For several laboratory tests, only ICD-10-CM codes are required for reimbursement. Some of the laboratory tests also require an additional code for reimbursement, which provides the medical necessity to perform tests. Since 2011, CMS covers screening for chlamydia, gonorrhea, syphilis, HIV, and HPV with the appropriate FDA-approved lab tests used with FDA-approved labeling and in compliance with CLIA regulations when ordered by a primary care provider, and performed by an eligible Medicare provider for these services.
However, stigma related to voluntary testing and critical regulatory compliance forms are the restraints for the market. However, global initiatives along with development in healthcare infrastructure are projected to provide platform for the market growth.
STDs testing market is segmented into laboratory and point-of-care testing devices. Based on laboratory testing devices, the market is divided into PCR, immunochromatographic capillary flow dipstick technology (assays), flow cytometry, differential light scattering, and enzyme-linked immunosorbent assay (ELISA). On the basis of point-of-care testing devices, the market is further segmented into rapid diagnostic kits, phone chips, microfluidics, and immunochromatographic tests. Currently, laboratories perform bulk of the tests, and are anticipated to continue to hold larger share of the market, both in terms of volume and revenue.
Flow cytometry is expected to grow fastest, owing to its cost-effectiveness and accuracy of these tests for the diagnosis of STDs in laboratories. However, trained personnel and expensive equipment are required for using this technology, which can be a prime cause of concern.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
- The report provides a quantitative analysis for the period of 2014‐2022 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on technology helps to understand the type of devices used to treat STDs.
- Extensive analysis of the market is conducted by following key technology positioning and by monitoring the top contenders within the market framework.
- Polymerase chain reaction (PCR)
- Immunochromatographic capillary flow dipstick technology (assay)
- Flow cytometry
- Differential light scattering
- Enzyme-linked immunosorbent assay (ELISA)
- Phone chips
- Immunochromatographic tests (ICTs)
- Rapid diagnostic kits